MedTrace Logo

A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA)

NCT04803006 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2026-02-06

No results posted yet for this study

Summary

The purpose of this study is to determine the optimal regimen for the use of siplizumab, a human anti-CD2 antibody, combined with donor bone marrow cells and non-myeloablative conditioning, for tolerance induction in living donor renal transplantation

Conditions

  • Kidney Transplantation

Interventions

BIOLOGICAL

TCD601

Investigational Product

Sponsors & Collaborators

  • ITB-Med LLC

    lead INDUSTRY

Principal Investigators

  • Tracy Killingsworth · Nefro Avillion

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-17
Primary Completion
2025-10-30
Completion
2025-10-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04803006 on ClinicalTrials.gov